Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting

BackgroundKEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous cell carcinoma (ESCC). There is no head-to-head comparison of pembrolizumab vs. nivolumab vs. camrelizumab in the second-line setting...

Full description

Bibliographic Details
Main Authors: Yi-Xin Zhou, Ping Chen, Yu-Ting Sun, Bei Zhang, Miao-Zhen Qiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
esophageal squamous cell carcinoma
PD-1 inhibitor
second line therapy
camrelizumab
nivolumab
pembrolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.698732/full

Similar Items

Similar Items